SCD - Latest News
LMP Capital and Income Fund Inc. (SCD), operates in Financial Services / Asset Management - Income, trades on NYSE.
Market capitalization stands near $5.01B.
The article list below shows the most recent SCD headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent SCD Headlines
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition
globenewswire.com - Oct 7, 2026
Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1. 7 million U.
Roche launches newborn screening test for three severe genetic conditions
gurufocus.com - Sep 30, 2026
Roche launches newborn screening test for three severe genetic conditionsPR NewswireBERLIN, Sept.
SCD: High Midstream/Low Bond Exposure Is A Good Combination
seekingalpha.com - Sep 2, 2026
LMP Capital & Income Fund offers a 9. 23% yield, emphasizing income and inflation protection via high allocations to MLPs and midstream energy equitie
10 Best CEFs This Month: Average Yield Of Near 10% (August 2026)
seekingalpha.com - Aug 29, 2026
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% yield and nearly 5%
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
prnewswire.com - Jul 28, 2026
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In ord
Frequently asked SCD news questions
- What is the latest SCD news headline?
- The most recent SCD headline (Oct 7, 2026) is "FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the SCD news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What SCD news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual SCD options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.